Casi Pharmaceuticals reports Fy24 EPS ($2.56) vs. ($2.02) last year

Reports FY24 revenue $28.5M vs. $33.9M last year. Wei-Wu He, CEO commented, “2024 was a transformative year for CASI as we strategically pivoted our company toward the development of CID-103 for organ transplant rejection and autoimmune disease. CID-103 is an anti-CD38 antibody with the potential to be a best-in-class treatment for a myriad of autoimmune diseases as well as antibody mediated rejection. We are encouraged by our clinical progress, achieving a milestone with the first Immune Thrombocytopenia patient dosed in January 2025. Simultaneously, we are diligently working towards resolution of the FDA renal allograft AMR clinical hold. As we advance into 2025, we remain firmly committed to progressing CID-103 at an accelerated pace. We expect to reach multiple important milestones this year. Our focused approach and prudent capital allocation position CASI to deliver sustainable long-term value creation for both patients and shareholders.”